UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 88-2805017 (S ...

Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Tony Butler – ROTH Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Panbela Therapeutics Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After management’s prepared remarks, there will be ...

[PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29%2E) Unaudited H1 2022 financials show a significant net loss increase from a $17.7 million IPR&D write-off, leading to a stockholders' deficit and going concern doubt [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2022, the company's financial position significantly declined, with total assets decreasing to $6.6 million, liabilities increasing to $11.4 million, and stockholders' equity shifting to a $4.8 million deficit Financial Metric Comparison (In thousands) | Financial Metric (In thousands) | June 30, 2022 (Unaudited) | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $2,530 | $11,867 | | Total current assets | $3,456 | $12,279 | | Total assets | $6,557 | $12,872 | | **Liabilities & Equity** | | | | Total current liabilities | $6,201 | $2,660 | | Total liabilities | $11,395 | $2,660 | | Total stockholders' (deficit) equity | $(4,838) | $10,212 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For H1 2022, net loss surged to $25.8 million from $4.4 million, primarily due to a $17.7 million IPR&D write-off, increasing loss per share to $1.84 Operating Results and Net Loss (In thousands, except per share) | Metric (In thousands, except per share) | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | General and administrative | $3,053 | $2,391 | | Research and development | $22,236 | $2,084 | | Operating loss | $(25,289) | $(4,475) | | Net loss | $(25,796) | $(4,443) | | Basic and diluted net loss per share | $(1.84) | $(0.44) | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $8.7 million in H1 2022, with no financing proceeds, leading to a $9.3 million decrease in cash and equivalents Cash Flow Summary (In thousands) | Cash Flow Activity (In thousands) | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(8,680) | $(3,658) | | Net cash used in investing activities | $(655) | $0 | | Net cash provided by financing activities | $0 | $1,042 | | Net change in cash | $(9,337) | $(2,617) | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the CPP acquisition as an asset purchase with a $17.7 million IPR&D write-off, new debt, and substantial doubt about the company's going concern due to an $82.0 million accumulated deficit - On June 15, 2022, Panbela acquired Cancer Prevention Pharmaceuticals, Inc. (CPP), which became a wholly-owned subsidiary, accounted for as an **asset acquisition**[24](index=24&type=chunk)[49](index=49&type=chunk) - The company has incurred **losses of $82.0 million** since its inception in 2011 and had a **net loss of $25.8 million** for the six months ended June 30, 2022, raising substantial doubt about its ability to continue as a going concern[26](index=26&type=chunk)[27](index=27&type=chunk) - The acquisition of CPP involved total consideration of **$10.3 million**, primarily allocated to In-Process Research and Development (IPR&D) of **$17.7 million**, which was immediately expensed to R&D[54](index=54&type=chunk)[39](index=39&type=chunk) - As part of the CPP acquisition, the company assumed debt, including a **$6.2 million note payable** to Sucampo GmbH and a **$0.7 million note** to Tillotts Pharma AG[55](index=55&type=chunk)[56](index=56&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations%2E) Management discusses the CPP acquisition and drug candidates, highlighting a significant increase in R&D expenses and net loss due to a $17.7 million IPR&D write-off, with urgent need for capital to fund operations beyond Q4 2022 - The company's lead candidates are **ivospemin (SBP-101)** for pancreatic cancer and **Flynpovi (eflornithine and sulindac)**, with a new global randomized trial for ivospemin, ASPIRE, initiated in January 2022[73](index=73&type=chunk)[77](index=77&type=chunk) - The acquisition of CPP resulted in a **non-cash write-off of approximately $17.7 million** from IPR&D, which was the primary driver of the increased net loss for the period[89](index=89&type=chunk)[90](index=90&type=chunk) - The company's cash balance of **$2.5 million** as of June 30, 2022, is only expected to fund operations until early in the fourth quarter of 2022, making additional capital raising critical[91](index=91&type=chunk)[92](index=92&type=chunk) Operating Results (In thousands) | Operating Results (In thousands) | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $20,028 | $985 | $22,236 | $2,084 | | Total operating expenses | $21,286 | $2,226 | $25,289 | $4,475 | | Net Loss | $(22,130) | $(2,186) | $(25,796) | $(4,443) | [Quantitative and Qualitative Disclosure About Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosure%20About%20Market%20Risk%2E) As a smaller reporting company, Panbela Therapeutics is not required to provide disclosure for this item - The company is **not required to provide disclosure** pursuant to this item because it qualifies as a smaller reporting company[119](index=119&type=chunk) [Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures%2E) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2022, despite a significant deficiency in personnel for segregation of duties, mitigated by senior management review - Management, including the CEO and CFO, concluded that **disclosure controls and procedures were effective** as of June 30, 2022[122](index=122&type=chunk) - The company has a **significant deficiency in internal control** due to insufficient personnel resources for segregation of duties, which is mitigated by executive and senior management review[120](index=120&type=chunk) - **No material changes** in internal control over financial reporting were identified during the most recent fiscal quarter[123](index=123&type=chunk) [PART II – OTHER INFORMATION](index=25&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings%2E) The company reported no material legal proceedings, though Note 9 to the financial statements discloses an ongoing arbitration with a former CFO of the acquired subsidiary, CPP - The company states there are **no legal proceedings to report** under this item[126](index=126&type=chunk) - Note 9 of the financial statements discloses that subsidiary CPP is in **arbitration with a former chief financial officer** over a termination for cause in November 2020, with the company defending against the claim[59](index=59&type=chunk) [Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors%2E) This section outlines significant risks, including the company's pre-revenue status, history of losses, and a "going concern" qualification, highlighting an urgent need for additional capital, successful CPP integration, and managing clinical trial uncertainties - The company has a history of **negative operating cash flow** and its auditors have expressed **substantial doubt about its ability to continue as a 'going concern'**[129](index=129&type=chunk)[131](index=131&type=chunk) - The company will require **additional capital** to continue operations beyond early Q4 2022 and may be forced to cease operations if it cannot secure funding[133](index=133&type=chunk) - The recent acquisition of CPP introduces **substantial risks**, including integration difficulties, unforeseen costs and liabilities, and potential disruption to ongoing business[151](index=151&type=chunk)[152](index=152&type=chunk)[153](index=153&type=chunk) - Clinical trials are **expensive, time-consuming, and highly uncertain**, with failure to demonstrate safety and efficacy materially harming the business[157](index=157&type=chunk)[158](index=158&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=36&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds%2E) The company reported no unregistered sales of equity securities or use of proceeds during the reporting period - **None**[196](index=196&type=chunk) [Defaults Upon Senior Securities](index=36&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities%2E) The company reported no defaults upon its senior securities - **None**[197](index=197&type=chunk)[199](index=199&type=chunk) [Mine Safety Disclosures](index=38&type=section&id=Item%204.%20Mine%20Safety%20Disclosures%2E) This item is not applicable to the company's business - **Not applicable**[201](index=201&type=chunk) [Other Information](index=38&type=section&id=Item%205.%20Other%20Information%2E) The company reported no information under this item - **None**[202](index=202&type=chunk) [Exhibits](index=38&type=section&id=Item%206.%20Exhibits%2E) This section lists all exhibits filed with the Form 10-Q, including the merger agreement, corporate governance documents, financing agreements, and required certifications - The report includes a list of filed exhibits, such as the **merger agreement**, **corporate governance documents**, **financing agreements**, and **required certifications**[203](index=203&type=chunk)[204](index=204&type=chunk)

Panbela Therapeutics Inc. (OTCQB:PBLA) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants James Carbonara – Managing Partner-Hayden IR, Inc. Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Robin Garner – Craig-Hallum Tony Butler – Roth Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Panbela Therapeutics First Quarter 2022 Earnings Call. At this time, all participants are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-0543922 (St ...

Panbela Therapeutics Inc. (OTCQB:PBLA) Q4 2021 Earnings Conference Call March 24, 2022 4:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - President & Chief Executive Officer Susan Horvath - Vice President & Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim group Tony Butler - ROTH Capital Robin Garner - Craig-Hallum Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39468 PANBELA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 7 ...

Company Overview November 2021 Last modified on 11/11/21 Cautionary Statements Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "anticipate," "believe," "continue," "estimate," "expe ...

Panbela Therapeutics Inc. (OTCQB:PBLA) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Robin Garner - Craig-Hallum Tony Butler - ROTH Capital Operator Good afternoon, ladies and gentlemen, and welcome to Panbela Therapeutics' Third Quarter 2021 Earnings Call [Operator Instructions]. It is my pleasure to turn the floor over to y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-0543922 ...